Making earlier cancer detection a routine part of medical care
EXACT SCIENCES
(In thousands)
Net loss
Interest expense
Depreciation and amortization
Income tax benefit
EBITDA (¹)
Stock-based compensation (2)
Investment loss (income)
Acquisition and integration costs
(3)
Reduction-in-force severance (4)
EXACT SCIENCES CORPORATION
Selected Unaudited Financial Information
EBITDA and Adjusted EBITDA Reconciliations
(Amounts in thousands)
Loss on sale of asset and divestiture related costs (5)
Impairment of long-lived assets (6)
Legal settlement (7)
Adjusted EBITDA
Three Months Ended September Nine Months Ended September
30,
30,
$
2022
(148,761) $
5,235
48,569
(166,938)
4,680
46,200
(3,116)
(3,858)
$ (98,073) $ (119,916)
58,328
66,855
8,584
4,093
(4,992)
10,150
$
17,165
5,946
2021
(13,042)
20,210
10,064
(8,544)
For associated footnotes, please refer to the table in the third quarter 2022 results press release
labeled EBITDA and Adjusted EBITDA Reconciliations
2022
(495,761) $
14,224
148,077
(6,882)
(340,342)
188,303
13,790
(54,695)
14,613
17,256
12,537
2021
(375,014)
13,948
135,221
(242,638)
(468,483)
198,869
(30,524)
141,401
20,210
10,064
(148,538) $ (128,463)
16View entire presentation